Finasteride-d9

Finasteride-d9 is deuterium labeled Finasteride. Finasteride (MK-906) is a potent and competitive 5α-reductase inhibitor, with an IC50 of 4.2 nM for type II 5α-reductase. Finasteride has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia[1][2][3].

Product Specifications

CAS Number

[1131342-85-2]

Product Name Alternative

MK-906-d9

UNSPSC

12352005

Hazard Statement

H302, H361, H412

Target

5 alpha Reductase; Isotope-Labeled Compounds

Type

Isotope-Labeled Compounds

Related Pathways

Metabolic Enzyme/Protease; Others

Applications

Cancer-programmed cell death

Field of Research

Cancer

Purity

99.13

Solubility

10 mM in DMSO

Smiles

C[C@@]12[C@](CC[C@@H]2C(NC(C([2H])([2H])[2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])=O)([H])[C@@]3([H])[C@@](CC1)([H])[C@@]4([C@@](NC(C=C4)=O)([H])CC3)C

Molecular Formula

C23H27D9N2O2

Molecular Weight

381.60

Precautions

H302, H361, H412

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Flores E, et, al. Steroid 5alpha-reductase inhibitors. Mini Rev Med Chem. 2003 May;3 (3) :225-37.|[3]Sirinarumitr K, et, al. Effects of finasteride on size of the prostate gland and semen quality in dogs with benign prostatic hypertrophy. J Am Vet Med Assoc. 2001 Apr 15;218 (8) :1275-80.|[4]Yun DK, et, al. Finasteride Increases the Expression of Hemoxygenase-1 (HO-1) and NF-E2-Related Factor-2 (Nrf2) Proteins in PC-3 Cells: Implication of Finasteride-Mediated High-Grade Prostate Tumor Occurrence. Biomol Ther (Seoul) . 2013 Jan;21 (1) :49-53.